Company news

Shanghai Allist Pharmaceuticals Co. Ltd. news in 2025

Shanghai Allist Pharmaceuticals Co. Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation

December 25, 2025

Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management

December 15, 2025

Announcement on Voluntary Disclosure of the Inclusion of the Company’s Innovative Drugs in the Updated National Medical Insurance Catalog

December 7, 2025

Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative

November 27, 2025

Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025

November 4, 2025

Report for Q3 2025

October 28, 2025

Announcement on Result of Shareholding Reduction by Shareholder

September 24, 2025

Indicative Announcement on Change in Equity of Shareholder Reaching 1% Scale

September 12, 2025

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

September 8, 2025

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

September 2, 2025

Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025

August 26, 2025

Announcement on Shareholding Reduction Plan for Shareholders

August 8, 2025

Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

July 9, 2025

Announcement on Voluntary Disclosure of Obtaining the 25th China Patent Gold Award

June 8, 2025

Announcement on Implementation of Dividend Distribution for 2024

May 22, 2025

Announcement on Resolution of the 2024 Annual General Meeting

May 14, 2025

Report for Q1 2025

April 23, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 25, 2025

Annual Earnings Preannouncement for 2024

January 20, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Drug Clinical Trial Approval for New Indications of Furmonertinib

January 17, 2025